The Innovative Canadian Pharmacogenomic Screening Initiative in Community Pharmacy (ICANPIC) study

JAPhA; July, 2017

The safety and efficacy of medications can vary significantly between patients as a result of genetic variability. As genomic screening technologies become more widely available, pharmacists are ideally suited to use such tools to optimize medication therapy management.

Download .pdf 

Can PGx help your members and improve plan sustainability, Plans & Trusts, 2017

June, 2017

By enhancing the ability of doctors to select prescription drugs that better interact with an individual’s inherited genetic variations, pharmacogenetics may hold a key to improving medical experiences for members and reducing plan costs.

Download .pdf 

Pharmacogenetic Testing May Improve Drug Treatments and Shorten Disability Leaves, Benefits Quarterly, 2017

March, 2017

This article describes how methods of personalized medicine – spedifically, pharmacogenetic (PGx) testing – can benefit private health plans, benefits managers, care providers and consumers alike.

Download .pdf 

Personalized Medicine: DNA pioneers

Canadian HealthCareNetwork; March 10, 2016

Watch Video

Written by Brett Ruffell on March 10, 2016 for
Toronto pharmacy partners with genetic testing firm to assess potential for pharmacogenomics in community pharmacy.

Download .pdf 

Your pharmacist’s secret weapon: How your DNA can help perfect your medication

The Globe and Mail; February 14, 2016

Catherine McLeod suffered one of her worst drug reactions – a minor stroke – while behind the wheel. She drove through a red light, and an oncoming vehicle totalled her car.

No one was seriously injured. But after the accident in 2005, she experienced two more minor strokes and kidney damage because of the litany of medications she was taking for bipolar disorder, diabetes and other conditions, she said. “I was overmedicated.”

Download .pdf 

Proposed Regulatory Framework for Direct-to-Consumer Genetic Testing: Diagnostics vs. Genetic Screening

Clinical Chemistry; September 18, 2014
On December 6, 2013, 23andMe stopped marketing direct-to- consumer (DTC)1 disease-predictive genetic testing to comply with the FDA’s directive. Although the FDA’s action was intended to protect the American public from questionable disease risk predictions, we believe the agency failed to assess all the benefits of DTC testing…
Download .pdf

Application of personalized medicine to chronic disease: a feasibility assessment

Clinical and Translational Medicine; December 18, 2013
Personalized Medicine has the potential to improve health outcomes and reduce the cost of care; however its adoption has been slow in Canada. Bridgepoint Health is a complex continuous care provider striving to reduce the burden of polypharmacy in chronic patients. The main goal of the study was to explore the feasibility of utilizing personalized medicine in the treatment of chronic complex patients as a preliminary institutional health technology assessment…
Download .pdf